CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 18, 2026, 4:00 PM EST
CNBX Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
160.58K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | - | - | - |
| Aug 31, 2024 | 130.07K | -280.09K | -68.29% |
| Aug 31, 2023 | 410.17K | 380.21K | 1,269.13% |
| Aug 31, 2022 | 29.96K | - | - |
| Aug 31, 2021 | - | - | - |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Carisma Therapeutics | 52.63M |
| Endonovo Therapeutics | 255.72K |
| Regen BioPharma | 236.56K |
| GB Sciences | 97.24K |
| Affymax | 42.00K |
CNBX Pharmaceuticals News
- 4 years ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 4 years ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 4 years ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 4 years ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 4 years ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 4 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 4 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire
- 5 years ago - CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials - PRNewsWire